In cancer, overexpression of TGF-β is closely associated with metabolic disorders, dysfunction, epithelial–mesenchymal transition, immune deficits, and cancer progression (Su et al., 2020; Liu et al., 2021). This evidence concerns the gene TGFB1 and metabolic disease.